US2024002502A1PendingUtilityA1

Anti-cd33 and anti-cd7 combination treatment

49
Assignee: BIVICTRIX LTDPriority: Nov 27, 2017Filed: Jun 29, 2023Published: Jan 4, 2024
Est. expiryNov 27, 2037(~11.3 yrs left)· nominal 20-yr term from priority
Inventors:Tiffany Jane Daniels
A61K 35/17C07K 16/2803A61K 2039/505C07K 2317/31C07K 2317/55C07K 2317/77C07K 2319/55A61P 35/02C07K 2317/732
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to the dual targeting of cell inhibiting agents to the cell surface receptors CD7 and CD33 in the treatment of hematological malignancy. In particular, the invention relates to cell inhibiting agents that bispecifically binds to CD33 and CD7 for use in the treatment of a CD7+CD33+ hematological malignancy. Such agents may comprise bispecific antibody drug conjugates.

Claims

exact text as granted — not AI-modified
1 - 55 . (canceled) 
     
     
         56 . A method of treating a CD7+CD33+ hematological malignancy by administering a cell inhibiting agent that bispecifically binds to CD33 and CD7 wherein said cell inhibiting agent comprises a chimeric antigen receptor T cell or NK cell comprising a bispecific antibody or an antigen binding portion thereof with a CD7 binding portion and a CD33 binding portion. 
     
     
         57 . (canceled) 
     
     
         58 . The method of treating the CD7+CD33+ hematological malignancy according to  claim 56 , wherein said hematological malignancy is AML. 
     
     
         59 . (canceled) 
     
     
         60 . The method of treating the CD7+CD33+ hematological malignancy according to  claim 56 , wherein said cell inhibiting agent is a bispecific anti-CD33 anti-CD7 CAR-T. 
     
     
         61 . (canceled) 
     
     
         62 . (canceled) 
     
     
         63 . (canceled) 
     
     
         64 . The method of treating the CD7+CD33+ hematological malignancy according to  claim 56 , wherein the T cell comprises a CD33+ T cell, a CD7+ T cell, or a combination thereof. 
     
     
         65 . (canceled) 
     
     
         66 . The method of treating the CD7+CD33+ hematological malignancy according to  claim 56 , wherein said CD33 binding portion comprises an antigen binding fragment of an antibody. 
     
     
         67 . The method of treating the CD7+CD33+ hematological malignancy according to  claim 56 , wherein said CD7 binding portion comprises an antigen binding fragment of an antibody. 
     
     
         68 . (canceled) 
     
     
         69 . (canceled) 
     
     
         70 . (canceled)

Join the waitlist — get patent alerts

Track US2024002502A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.